The Valley Desk

NCT06708949 · Interventional trial

A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

Overall registry status Active not recruiting

Phase 2

Conditions Renal Cell Carcinoma, Clear Cell

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov